Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.

Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.

The company abandons TNG908, but is still all in on the troubled target.

Reports of Arc-10's failure are greatly exaggerated, the company argues.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.